AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22110246 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc 12.5 IU/kg
Number of subjects: 14
Study 22110246 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc 25 IU/kg
Number of subjects: 14
Study 22110246 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc 50 IU/kg
Number of subjects: 14
Study 22110246 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc 100 IU/kg
Number of subjects: 14
Study 22110246 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc
Number of subjects: 14
Study 22113871 — intervention group
Group type: EXPERIMENTAL
Intervention: (58)Fe-heme
Number of subjects: 19
Study 22113871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nonheme Fe
Number of subjects: 19
Study 22113871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary heme Fe
Number of subjects: 19
Study 22113871 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Hb
Number of subjects: 19
Study 22114900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml, 20 ml infiltration
Number of subjects: 46
Study 22114900 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 46
Study 22114900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml
Number of subjects: 46
Study 22115397 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy initiation
Number of subjects: 0
Study 22115397 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22115634 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of Tdap vaccine (naïve group)
Number of subjects: 769
Study 22115634 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat dose of Tdap vaccine (repeat-dose group)
Number of subjects: 769
Study 22115634 — intervention group
Group type: COMPARATOR
Intervention: Naïve group
Number of subjects: 769
Study 22115634 — intervention group
Group type: COMPARATOR
Intervention: Repeat-dose group
Number of subjects: 769
Study 22115661 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 6183
Study 22115661 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 6183
Study 22116796 — intervention group
Group type: EXPERIMENTAL
Intervention: LVR-coil treatment
Number of subjects: 16
Study 22117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive risk stratification tests including beat-to-beat variability of repolarization (BVR), T-wave alternans, T-wave morphology variables, ambient arrhythmias from Holter, heart rate variability, and heart rate turbulence.
Number of subjects: 700
Study 22117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive programmed electrical stimulation for assessing inducibility of ventricular arrhythmias.
Number of subjects: 700
Study 22117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for variants in established candidate genes related to arrhythmogenomic risk.
Number of subjects: 700
Study 22117586 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A H1N1/09 AS03 adjuvanted vaccine (3.75 mg of haemagglutinin, two doses at 3-4 week interval)
Number of subjects: 110
Study 22117890 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of automated telephonic symptom assessment (ATSA) plus web-based notification of symptom severity and problem solving advice to their chosen caregiver
Number of subjects: 300
Study 22117890 — intervention group
Group type: COMPARATOR
Intervention: 10 weeks of automated telephonic symptom assessment (ATSA) alone
Number of subjects: 300
Study 22117897 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 22117897 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Bleeding Scale
Number of subjects: 0
Study 22118061 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and chiropractic care (A/C)
Number of subjects: 0
Study 22118061 — intervention group
Group type: COMPARATOR
Intervention: Traditional CMP services
Number of subjects: 0
Study 22118987 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity monitoring using a multisensory armband
Number of subjects: 134
Study 22121927 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral Inventory for Depression (IID) scale
Number of subjects: 1629
Study 22123298 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemiluminescence (ECL) assay for insulin autoantibodies (IAA)
Number of subjects: 93
Study 22123298 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemiluminescence (ECL) assay for anti-insulin antibodies (IA)
Number of subjects: 93
Study 22123298 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiobinding assay (RBA)
Number of subjects: 93
Study 22126422 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 22126422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22127070 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT)
Number of subjects: 127
Study 22127692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 208
Study 22127692 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus anti-tumor necrosis factor
Number of subjects: 208
Study 22127692 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 208
Study 22127697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor α (TNFα) inhibitors
Number of subjects: 0
Study 22127844 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan therapy
Number of subjects: 10
Study 22127844 — intervention group
Group type: COMPARATOR
Intervention: Observation period
Number of subjects: 10
Study 22127927 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib, a pan-VEGF receptor tyrosine kinase inhibitor
Number of subjects: 30
Study 22129044 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus and low-dose oral cyclophosphamide
Number of subjects: 0
Study 22129044 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22129253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (1.5 million IU per day for 5 days, followed by three 5-day courses of 3 million IU per day at weeks 3, 6, and 9)
Number of subjects: 10
Study 22129252 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous interleukin-2 (0.3×10(6), 1×10(6), or 3×10(6) IU per square meter of body-surface area) for 8 weeks
Number of subjects: 29
Study 22129980 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22130101 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 3
Study 22130101 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 3
Study 22131611 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 57
Study 22131611 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Anxiety and Depression Scale (HADS) in severely depressed subgroup
Number of subjects: 57
Study 22131611 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI) in participants without depression
Number of subjects: 57
Study 22133624 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 to 120 mg/day
Number of subjects: 0
Study 22133624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22133770 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab 10 mg/day for 3 days and intravenous rituximab 100 mg on Days +4, +11, +18, and +25
Number of subjects: 15
Study 22133771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat + gemtuzumab ozogamicin
Number of subjects: 31
Study 22133772 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Number of subjects: 69
Study 22133778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels measured post-transplant
Number of subjects: 0
Study 22134145 — intervention group
Group type: EXPERIMENTAL
Intervention: sdNVP
Number of subjects: 192
Study 22134145 — intervention group
Group type: EXPERIMENTAL
Intervention: sdNVP/CBZ
Number of subjects: 192
Study 22134563 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% EF foam
Number of subjects: 30
Study 22135716 — intervention group
Group type: EXPERIMENTAL
Intervention: SupaKids project
Number of subjects: 0
Study 22137491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer therapies (specifics not provided)
Number of subjects: 71
Study 22137491 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylating agent dose score
Number of subjects: 71
Study 22137491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation exposure
Number of subjects: 71
Study 22137491 — intervention group
Group type: COMPARATOR
Intervention: High-dose cancer therapy
Number of subjects: 71
Study 22137663 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels in type 2 diabetes patients
Number of subjects: 82
Study 22137663 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 82
Study 22139909 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-520 single-dose schedule (dose levels: 2.5, 3.75, 4.5, and 5.6 mg/m(2))
Number of subjects: 36
Study 22139909 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-520 divided-dose schedule (dose levels: 0.8, 1.2, 1.5, and 1.8 mg/m(2)/day)
Number of subjects: 36
Study 22139909 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-520 (both schedules)
Number of subjects: 36
Study 22140209 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper prescriptions
Number of subjects: 78
Study 22140424 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure to interferon-beta-1b
Number of subjects: 0
Study 22140424 — intervention group
Group type: COMPARATOR
Intervention: Low exposure to interferon-beta-1b
Number of subjects: 0
Study 22141572 — intervention group
Group type: EXPERIMENTAL
Intervention: +183 G-allele
Number of subjects: 1001
Study 22141572 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 1001
Study 22141572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes type 2 and metabolic syndrome
Number of subjects: 1001
Study 22141572 — intervention group
Group type: EXPERIMENTAL
Intervention: +183 AA genotype
Number of subjects: 1001
Study 22141572 — intervention group
Group type: EXPERIMENTAL
Intervention: +183 G-alleles
Number of subjects: 1001
Study 22145021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intestinal permeability in PD subjects
Number of subjects: 2
Study 22145021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal mucosa staining for E. coli bacteria, nitrotyrosine, and alpha-synuclein
Number of subjects: 2
Study 22145021 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum LBP levels
Number of subjects: 2
Study 22145021 — intervention group
Group type: COMPARATOR
Intervention: Intestinal permeability
Number of subjects: 2
Study 22145984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg b.i.d.
Number of subjects: 12
Study 22145984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg b.i.d.
Number of subjects: 12
Study 22145984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg b.i.d.
Number of subjects: 12
Study 22145984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (all doses)
Number of subjects: 12
Study 22146496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 320-row computed tomography angiography (CTA) and myocardial CT perfusion imaging (CTP)
Number of subjects: 16
Study 22146496 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary angiography and single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI)
Number of subjects: 16
Study 22146496 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary angiography alone
Number of subjects: 16
Study 22147631 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI) treatment for depression for 2 weeks
Number of subjects: 201
Study 22149959 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of scAAV2/8-LP1-hFIXco
Number of subjects: 6
Study 22149959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose of scAAV2/8-LP1-hFIXco
Number of subjects: 6
Study 22149959 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of scAAV2/8-LP1-hFIXco
Number of subjects: 6
Study 22149959 — intervention group
Group type: EXPERIMENTAL
Intervention: scAAV2/8-LP1-hFIXco (all doses)
Number of subjects: 6
Study 22151886 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+/MC+
Number of subjects: 69
Study 22151886 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-/MC+
Number of subjects: 69
Study 22151886 — intervention group
Group type: COMPARATOR
Intervention: HIV+ and HIV- with MC
Number of subjects: 69
Study 22151886 — intervention group
Group type: COMPARATOR
Intervention: HIV+ and HIV- without MC
Number of subjects: 69
Study 22152120 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (EIA: etoposide 125 mg/m² iv days 1 and 4, ifosfamide 1500 mg/m² iv days 1 - 4, doxorubicin 50 mg/m² day 1, pegfilgrastim 6 mg sc day 5) followed by definitive surgery with intra-operative radiotherapy, adjuvant radiotherapy and 4 adjuvant cycles of EIA.
Number of subjects: 50
Study 22152155 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index at baseline
Number of subjects: 95
Study 22152155 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index and age after three years
Number of subjects: 95
Study 22152155 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRC after three years
Number of subjects: 95
Study 22152155 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRC, FEV1, and number of exacerbations after three years
Number of subjects: 95
Study 22152155 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ total score
Number of subjects: 95
Study 22152155 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity domain of SGRQ
Number of subjects: 95
Study 22152427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports Drink (SPD: CHOs 68.6 g.L-1, BCAAs 4 g.L-1, caffeine 75 mg.L-1)
Number of subjects: 13
Study 22152427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports Drink (SPD)
Number of subjects: 13
Study 22152427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study 22153792 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg intravenous infusions at weeks 0, 2, 6, 14, and 22
Number of subjects: 215
Study 22153792 — intervention group
Group type: COMPARATOR
Intervention: Control group (etanercept)
Number of subjects: 215
Study 22153841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-alcamid
Number of subjects: 48
Study 22153841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sculptra
Number of subjects: 48
Study 22153841 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat transfer
Number of subjects: 48
Study 22153841 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study 22154731 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous wave-free ratio (iFR) measured during the wave-free period
Number of subjects: 157
Study 22154731 — intervention group
Group type: COMPARATOR
Intervention: Fractional flow reserve (FFR)
Number of subjects: 157
Study 22154789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 149
Study 22154789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Number of subjects: 149
Study 22154896 — intervention group
Group type: EXPERIMENTAL
Intervention: SODAS dexmethylphenidate 20 mg
Number of subjects: 18
Study 22154896 — intervention group
Group type: EXPERIMENTAL
Intervention: SODAS dexmethylphenidate 30 mg
Number of subjects: 18
Study 22154896 — intervention group
Group type: EXPERIMENTAL
Intervention: SODAS dexmethylphenidate 40 mg
Number of subjects: 18
Study 22154896 — intervention group
Group type: EXPERIMENTAL
Intervention: SODAS dexmethylphenidate (all doses)
Number of subjects: 18
Study 22155140 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel®, Amgen Inc.) 0.4 mg/kg/dose, subcutaneously, twice weekly, for 4 weeks (group A) or 12 weeks (group B)
Number of subjects: 34
Study 22155140 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (constant for initial 4 weeks, then tapered)
Number of subjects: 34
Study 22155453 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 9E18 targeting GPVI dimers
Number of subjects: 0
Study 22155453 — intervention group
Group type: COMPARATOR
Intervention: ADP receptor P2Y12 antagonists
Number of subjects: 0
Study 22155561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg
Number of subjects: 142
Study 22155561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 22156656 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy regimen (vinblastine 3 mg/m2 weekly for 7 weeks, cyclophosphamide 30 mg/m2 daily for 21 days, methotrexate 10 mg/m² twice weekly for 3 weeks, celecoxib 100 mg to 400 mg twice daily for 56 days)
Number of subjects: 16
Study 22156656 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy regimen
Number of subjects: 16
Study 22157326 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention over 12 weeks
Number of subjects: 115
Study 22157326 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain phase
Number of subjects: 115
Study 22157574 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical immunosuppression with cyclosporine
Number of subjects: 0
Study 22157574 — intervention group
Group type: EXPERIMENTAL
Intervention: General monitoring of patients with graft-versus-host disease
Number of subjects: 0
Study 22158386 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan (3 × 14 g/m²) and Fludarabine (5 × 30 mg/m²)
Number of subjects: 75
Study 22158386 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan/Fludarabine conditioning regimen
Number of subjects: 75
Study 22160069 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular blood transfusion therapy
Number of subjects: 0
Study 22160069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 0
Study 22160069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0
Study 22160069 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sibling donor HSCT
Number of subjects: 0
Study 22160069 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated HSCT
Number of subjects: 0
Study 22160298 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg daily and Erlotinib 150 mg daily
Number of subjects: 16
Study 22160384 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR-transduced T cells infusion after chemotherapy and IL-2 course
Number of subjects: 8
Study 22160384 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR-transduced T cells infusion
Number of subjects: 8
Study 22160487 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term nicotine incubation (1 μM) in schizophrenia smokers
Number of subjects: 0
Study 22160487 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison between schizophrenia smokers and healthy smokers
Number of subjects: 0
Study 22160487 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison between healthy smokers and never-smokers
Number of subjects: 0
Study 22161649 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet-induced weight loss intervention for 16 weeks
Number of subjects: 159
Study 22162141 — intervention group
Group type: EXPERIMENTAL
Intervention: StarClose Vascular Closure System (VCS)
Number of subjects: 171
Study 22162229 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberrant signaling pathways in pancreatic cancer
Number of subjects: 0
Study 22162470 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding with a lipid-enriched diet (+760 kcal/d) for 2 months
Number of subjects: 44
Study 22163120 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34(+) cells
Number of subjects: 0
Study 22163120 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacologic or revascularization treatment
Number of subjects: 0
Study 22165955 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB/IL2 (12 μg/kg; 4 daily doses; 21 day cycles)
Number of subjects: 60
Study 22168920 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with preterm birth (n = 114)
Number of subjects: 241
Study 22168920 — intervention group
Group type: COMPARATOR
Intervention: Matched controls with term births (n = 127)
Number of subjects: 241
Study 22169111 — intervention group
Group type: EXPERIMENTAL
Intervention: PMNs from AAA patients
Number of subjects: 22
Study 22169111 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL concentrations in AAA patients from France
Number of subjects: 22
Study 22169111 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL concentrations in AAA patients from Spain
Number of subjects: 22
Study 22169111 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL and retrospective AAA growth
Number of subjects: 22
Study 22169111 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL and prospective growth in Spanish and Australian patients
Number of subjects: 22
Study 22169779 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN-α for 9 months before and for 3 months following IM discontinuation
Number of subjects: 11
Study 22169779 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN-α therapy
Number of subjects: 11
Study 22169779 — intervention group
Group type: EXPERIMENTAL
Intervention: IM restart after cytogenetic relapse
Number of subjects: 11
Study 22169779 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients off IM therapy
Number of subjects: 11
Study 22169986 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab
Number of subjects: 0
Study 22169986 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 22170355 — intervention group
Group type: EXPERIMENTAL
Intervention: Edematous SAM group
Number of subjects: 19
Study 22170355 — intervention group
Group type: COMPARATOR
Intervention: Nonedematous SAM group
Number of subjects: 19
Study 22170355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19